Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers

NEW YORK, July 28, 2021 /PRNewswire/ — Bridge Medicines and Cornell University today announced an exclusive license agreement to develop UBR5 Inhibitors for the treatment of certain difficult-to-treat cancers such as triple-negative breast cancer (TNBC). UBR5 is a cellular enzyme (an E3 ubiquitin ligase) that is involved in the labelingContinue Reading